Keybanc Maintains Overweight on Baxter Intl, Lowers Price Target to $95
Keybanc analyst Matthew Mishan maintains Baxter Intl (NYSE:BAX) with a Overweight and lowers the price target from $98 to $95.
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell
• Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.
Keybanc Maintains Overweight on Baxter Intl, Raises Price Target to $98
Keybanc analyst Matthew Mishan maintains Baxter Intl (NYSE:BAX) with a Overweight and raises the price target from $92 to $98.
Hillrom Shareholders Approve Acquisition By Baxter; Hillrom Shareholders Will Receive $156/Share In Cash
Hillrom (NYSE:HRC) today announced that its shareholders have voted to approve the previously announced pending acquisition by Baxter International Inc. (NYCE: BAX) at a special meeting. Hillrom shareholders voted
Baxter Highlights New Data Indicating Sharesource Digital Health Platform For Home Dialysis May Improve Survival, Reduce Hospitalizations
Large, randomized study presented during American Society of Nephrology’s Kidney Week shows survival rates nearly two times higher in patients using remote patient management
These data suggest digital health
Morgan Stanley Maintains Equal-Weight on Baxter Intl, Lowers Price Target to $86
Morgan Stanley maintains Baxter Intl (NYSE:BAX) with a Equal-Weight and lowers the price target from $90 to $86.
Baxter Shares Fall Despite Better-Than-Expected Q3 Earnings, FY21 EPS Outlook Boost
Baxter International Inc (NYSE:BAX) posted Q3 revenue of $3.23 billion, in line with the consensus, up 9% on a reported…
Looking Into Baxter International’s Return On Invested Capital
According to Benzinga Pro, during Q3, Baxter International (NYSE:BAX) earned $513.00 million, a 20.99% increase from the preceding quarter. Baxter International also posted a total of $3.23 billion in sales, a 4.13% increase since Q2.
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Baxter International Q3 EPS $1.02 Beats $0.94 Estimate, Sales $3.23B Miss $3.23B Estimate
Baxter International (NYSE:BAX) reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of $0.94 by 8.51 percent. This is a 22.89 percent increase over earnings of $0.83 per share from